medicines transparency alliance08/08/2015 1 meta peru country overview public sector private sector...
TRANSCRIPT
Medicines Transparency Alliance19/04/23 1
MeTA Peru
Country OverviewPublic SectorPrivate SectorCivil Society
Medicines Transparency Alliance19/04/23 2
MeTA Peru
Germán Rojas, Technical SecretaryLeda M. Perez, Consultant to MeTA in Peru
Medicines Transparency Alliance19/04/23 3
Multi-stakeholder process
A commitment to engage– Received a commitment from the MoH in early 2008 to participate in MeTA– Participation of public and private sectors and civil society in MeTA global
launch of May, 2008
A commitment to proceed– Birth of the Grupo Impulsor, June 2008– MeTA Peru National Forum, November, 2008– Consolidation of Executive Committee and National Council between
November, 2008 and February, 2009– Refinement of MeTA Peru national work plan, February, 2009-February, 2010
A commitment to implement– Executive Committee continues to meet weekly to make decisions relative to
work plan implementation– National Council meets every two months to assess progress on work plan
Medicines Transparency Alliance
Major achievements and successes
All sectors remain at the table!– Continuous nature of multi stakeholder process– Communication has changed as a result of MeTA
Progress on key areas of implementation– Price Observatory– Public purchases study– Development of Centers for Medicines Information
Agreement on key areas to be implemented– Development of a national generics policy– Development of baseline data studies, i.e., pharmaceutical sector scan and
multi stakeholder process evaluation– Development of software for price observatory– Development of Website/communications plan
19/04/23 4
Medicines Transparency Alliance
Overall challenges
The multi stakeholder process takes time– Sectors are working together which may have never had a history of
collaboration– Without trust and relationships it is impossible to move the agenda forward.– Must adapt to new structures, i.e., Executive Committee, National Council,
administrative and technical secretariats
The Executive Committee and National Council lead this process and not the Technical or Administrative Secretariats– This means that there are many minds at work and the Technical and
Administrative Secretariats are beholden to the will of these voluntary bodies and not the other way around
19/04/23 5
Medicines Transparency Alliance
Lessons Learned
The multi stakeholder process may be a useful manner of creating transparency and improving decision-making in the pharmaceutical sector. However,– Investments in relationship- and trust-building are essential– Such a process is difficult anywhere in the world, but may be particularly
challenging in environments whose governments have been historically centralized.
While transparency in information about medicines and process is important, we must be careful that the mechanisms put in place do not create greater bureaucracies
There is value in a shared space between civil society, government and private sector to discuss common issues of concern.
19/04/23 6
Medicines Transparency Alliance
Lessons Learned
19/04/23 7
PUBLIC SECTOR
CIVILSOCIETIES
PRIVATESECTOR
• MINSA• EsSalud• Defensoría del Pueblo• Facultad de Medicina de la UNMSM • Gobiernos Regionales: Arequipa, Huánuco, Piura
• Asociación Nacional de Laboratorios Farmacéuticos– ALAFARPE• Asociación Nacional de Industrias Farmacéuticas – ADIFAN• Comisión de Salud de Cámara de Comercio de Lima (COMSALUD)• Asociación Peruana de Entidades Prestadoras de Salud (APEPS)
• Colegio Médico del Perú • Acción Internacional para la Salud • Foro Salud • Red Peruana de Pacientes y Usuarios
Medicines Transparency Alliance
Lessons Learned
19/04/23 8
PresidentVice-President15 Members
MoHOmbudsmanHAIMedical College of PeruALAFARPE
National Council MeTA Peru
Executive Committee MeTA Peru
Technical Secretariat
Communicator
AdministrativeSecretariat
Support: International consultant
Medicines Transparency Alliance19/04/23 9
Thank you
German Rojas, Technical Secretary
Leda M. Perez, Consultant to MeTA in Peru
Email: [email protected] and [email protected]
Mobile number: 511 99566 5509 (Leda) 511 999378102 (Germán)
Skype: leda568 and grojas3000
Website: www.metaperu.org
Medicines Transparency Alliance19/04/23 10
Peru – Public Sector
Melitón ArcePedro YarascaPedro Tintaya
Medicines Transparency Alliance19/04/23 11
Analytical Summary at the beginning of MeTA
What were the needs and problems in this specific sector at the beginning of MeTAProblems:
– Lax legislation for the Registration and Quality of medicines. – Little transparency in the information of prices.– Promotion and Publicity of medicines
Needs:
– Transparency in information of prices of Pharmaceutical Products
– Politics of Generic Medicines– Rational use of medicines: Listing of Essential Medicines of
the Health Sector– Greater availability and affordability of medicines
Medicines Transparency Alliance19/04/23 12
Registered medicines in Peru
Total of Medicines with Sanitary Registration in force: 23,022Fuente: SI-DIGEMID. Abril 2010
Nacional47%
Extranjero53%
Medicamentos de Marca
53%
Otros24%
Medicamento Generico
21%
Producto de origen
Biologico2%
Medicines Transparency Alliance
Main mailstones
What milestones have been reached during the MeTA pilot phase?
During the period of the MeTA pilot phase, the following milestones have been achieved, favored by MeTA Peru:
Observatoriy of Prices of Pharmaceutical Products:– Regulatory framework for the OPPF– Development of the software for prices reports– Technological support :PCs, Server– Informative campaigns for the dissemination of the OPPF: Informative Modules
Aspects that have facilitated to reach this milestones: – New legislation of Pharmaceutical Products, medical devices and sanitary
products. – Obligatory nature of prescription in International Common Denomination (DCI)
19/04/23 13
Medicines Transparency Alliance
Successes
What were the successes of the sector during the MeTA pilot phase?
– Elaboration and approval of the normative framework on the Observatory of Prices
– Launch of the Observatory of Prices - Currently in Version 2.
– Political commitment and support by the Minister of Health
– Acceptability of the Observatory of Prices by part of the population
19/04/23 14
Medicines Transparency Alliance19/04/23 15
Examples
Informative campaign on Prices of Medicines
Medicines Transparency Alliance
Challenges
What challenges have this sector to confront during the MeTA Pilot Phase?
– To build a better trust among the associates.
– The presence of divergent opinions during the process.
– Greater capacity in technological and human resources.
19/04/23 16
Medicines Transparency Alliance
Lessons Learned
What lessons has this sector learned of MeTA?
– Recognition of issues that should be revealed to the population (prices, availability, public purchases, information of medicines).
– Allowing space for multisectorial dialogue.
– Identification of objectives and common strategies among the associates, always respecting their points of view.
– It has permitted to identify prominent tissues for the country in matter
of medicines.
19/04/23 17
Medicines Transparency Alliance19/04/23 18
Thank you
Pedro Yarasca
e-mail: [email protected]
Telf.: 0051-1-998704127
www.digemid.minsa.gob.pe
Medicines Transparency Alliance19/04/23 19
Private Sector
Berenice PintoAugusto Rey
Medicines Transparency Alliance19/04/23 20
Analytical Summary at the beginning of MeTA
What were the needs and problems in this specific sector at the beginning of MeTA
• Quality
• Ilegal Market
• Ethics
• Regulation
Medicines Transparency Alliance
Main mailstones
What milestones have been reached during the MeTA pilot phase?
– Forming part of a roundtable where we are able to work together as a country on common interest (public, private and civil company).
– Communication among the private sector, the public sector and the civil company has improved.
– Communication of the companies that conform the private sector has improved (ADIFAN, ALAFARPE, COMSALUD-CCL).
– Joint appreciations as private sector on problems that normally require a major approach by the public sector.
19/04/23 21
Medicines Transparency Alliance
SuccessesWhat were the successes of the sector during the MeTA pilot phase?
– Diffusion within the private sector of MeTA's objectives – Achieving commitment of the private sector stakeholders
on access to medicines. – Permanent participation in MeTA Peru of 3 of the 4 private
sector stakeholders. – Commitment and participation of ALAFAL– Better communication both inter and intra-sectorial. – Greater understanding of the multi-stakeholder process.
19/04/23 22
Medicines Transparency Alliance
Challenges
What challenges has this sector confronted during the MeTA Pilot Phase?
– Sharing the concerns of the pharmaceutical sector.
– Contribute to a common agenda among private sector which is presented in MeTA Peru.
– Debate different points of view with other sectors .
19/04/23 23
Medicines Transparency Alliance
Lessons Learned
What lessons has this sector learned of MeTA?
– Opportunity of dialogue among sectors. – The multi-stakeholder process allows to identify
common problems. – Engage the opportunity that the government of
the United Kingdom has offered us, to discuss pharmaceutical issues with transparency.
– It is possible to build a shared vision across sectors.
– Building trust is necessary among the sectors
19/04/23 24
Medicines Transparency Alliance19/04/23 25
Thank you
Berenice Pinto
C-electrónico: [email protected]
Número Celular: 511 992776311 / 511 4226480
Página Web: www.adifan.com.pe
Augusto Rey
C-electrónico: [email protected]
Número Celular: 511 995491392 / 511 4410693
Página Web: www.alafarpe.com
Medicines Transparency Alliance19/04/23 26
Civil Society
Marco Alegre Romero – Coordination CSOs
Medicines Transparency Alliance19/04/23 27
Analytical Summary at the beginning of MeTA
What were the needs and problems in this specific sector at the beginning of MeTA?
43% of the country's population lacks access to essential medicines.
CSOs had not fluent access to essential critical information by the state and the private sector in relation to access to medicines.
There was limited space for Civil Society participation to generate public policy on essential medicines.
Absence of a National Policy for Generic Medicines.
Weakness in the mechanisms of transparency and accountability of public administration in the early stages of the medicines supply chain.
Medicines Transparency Alliance
Main mailstones
What milestones have been reached during the MeTA pilot phase?
Being able to start working together to address access to generic medicines, between the State, Civil Society and Private.
Forming a Coalition of Civil Society Organizations
To be able to formulate a national project by the CSOs Coalition and users, to train leaders in monitoring access to medicines.
19/04/23 28
Medicines Transparency Alliance
Successes
Which were the successes of the sector during the MeTA pilot phase?
Raise the issue about lack of access to medicines at national and regional levels.
Reach an agreement with the University for the development of post-graduate courses to train leaders in monitoring access to medicines.
Manage to jointly formulate a project that contribute to access of medicines among the national and regional CSOs
The engagement of 18 out of 25 regions of the country in the implementation of the project
19/04/23 29
Medicines Transparency Alliance
Challenges
What challenges has this sector confronted during the MeTA Pilot Phase?
To provide a better positioning of the CSOs on the National Council and the Executive Board of META Peru.
To achieve a cohesion between CSOs – Users, and technical people.
To engage active leaders in monitoring access to medicines at the national level articulated in the network.
19/04/23 30
Medicines Transparency Alliance
Lessons Learned
What lessons has this sector learned from MeTA? You can better address the problem of access to essential medicines when working in collaboration with the state, civil society and the private sector.
The Civil Society can improve the quality of dialogue and negotiation with the public and private sector when it has continuous access to information.
The Civil society is divided according to the interests of each of its members.
The regions of Peru would like to address the problems ofaccess to essential medicines but do not have strategies and information to give an appropriate response.
19/04/23 31
Medicines Transparency Alliance19/04/23 32
Thank you
Marco Alegre Romero
C-electrónico: [email protected]
Número Celular: (51) 1997273931
Skype:
Página Web: www.forosalud.org.pe